Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital

Diminishing Returns From Ultrahypofractionated Radiation Therapy for Prostate Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma

    Research output: Contribution to journalEditorialpeer-review

  2. Daily Adaptive Proton Therapy: Is it Appropriate to Use Analytical Dose Calculations for Plan Adaption?

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The Feasibility of Implementing Deep Inspiration Breath-Hold for Pediatric Radiation Therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE: More than a decade of randomized controlled trials in prostate cancer has established a positive radiation dose response at moderate doses and a consistently low α/β ratio in the linear quadratic model for moderate hypofractionation. The recently published large randomized trial of ultrahypofractionated prostate cancer radiation therapy adds substantially to our current knowledge of dose response and fractionation sensitivity.

METHODS AND MATERIALS: Randomized trials of dose escalation and hypofractionation of radiation therapy were meta-analyzed to yield the overall best estimate of the α/β ratio. Additionally, a putative saturation of dose effect previously reported at approximately 80 Gy EQD2 was investigated by mapping the relative effectiveness assessed at 5 years onto a single reference dose-response curve.

RESULTS: Meta-analysis of 14 randomized trials including 13,384 patients yielded a best estimate of α/β = 1.6 Gy (95% confidence interval, 1.3-2.0 Gy) but with highly significant heterogeneity (I2 = 70%, P = .0005). Further analysis indicated an association between increasing dose per fraction in the experimental arm and increasing α/β ratio (slope, 0.6 Gy increase in α/β per Gy increase in fraction size; P = .017). This deviation from the linear quadratic model could, however, also be explained by biochemical control maxing out at doses above approximately 80 Gy.

CONCLUSIONS: Biochemical control data from randomized controlled trials of dose-per-fraction escalation in prostate cancer radiation therapy are inconsistent with the presence of a constant fractionation sensitivity in the linear-quadratic model and/or a monotonic dose response for biochemical control beyond 80 Gy equivalent dose. These observations have a potential effect on the optimal doses in future trials and the interpretation of ongoing trials of ultrahypofractionation.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number2
Pages (from-to)299-304
Number of pages6
Publication statusPublished - 1 Jun 2020

ID: 60921748